This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam And The Alpha-1 Project (TAP) Form Collaboration For Advancement Of ALN-AAT, An RNAi Therapeutic In Development For The Treatment Of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease (Graphic: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have entered into a collaboration agreement for the continued advancement of ALN-AAT, a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. TAP’s mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency. TAP is partially funding research activities for ALN-AAT. Detailed financial terms of the research agreement were not disclosed. Alnylam remains on track to file an investigational new drug (IND) application for this program in mid-2015.

“We have assembled what we believe to be the industry’s most robust pre-clinical data package supporting advancement of ALN-AAT – an ‘Enhanced Stabilization Chemistry’ or ‘ESC’-GalNAc-siRNA conjugate targeting AAT – including results in rodent models that demonstrate knockdown of the disease-causing Z-allele and significant lowering of the mutant protein (Z-AAT) burden in the liver, with associated improvements in liver function, as seen by normalization of the proliferative index, improved liver pathology, attenuated tissue fibrosis, and decreased incidence of liver tumor formation. In addition, we believe we have confirmed the activity of ALN-AAT in non-human primate models and expect our Development Candidate to achieve human target gene knockdown at doses less than 1 mg/kg with a once-monthly dose regimen or better. Since our GalNAc-siRNA platform is clinically validated based on results from other Alnylam RNAi therapeutic programs, we have a high level of confidence that ALN-AAT can achieve potent knockdown of the disease-causing Z-allele protein with subcutaneous dose administration and a favorable safety profile,” said Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam. “Accordingly, we are fully committed to the continued advancement of our RNAi therapeutic to patients with AAT deficiency with associated liver disease. This new recognition from TAP, part of the leading patient advocacy group for people afflicted with AAT deficiency, brings our efforts closer to patients in need and to their caregivers. We continue to expect that we will file our IND or IND equivalent for ALN-AAT in mid-2015.”

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.30 -0.92%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $233.92 0.69%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs